NIH Signed a 10-Year Agreement That Could Move $2 Billion of Infectious Disease Research to the Pentagon

On August 4, 2026, the Defense Department's biodefense chief signed a memorandum of agreement with the National Institutes of Health. NIH Director Jay Bhattacharya signed it the following day. Neither agency announced it. Congress learned about it roughly a month later, when Democratic members of the House Appropriations Committee pressed NIH for information and then made the existence of the agreement public on September 3, 2026.

The document runs through 2036. It names no dollar amount. Reporting by Nature, Science, and The New York Times over the following week established the figure everyone is now citing: the arrangement could move up to $2 billion in NIH research funds to the Department of Defense, drawn from the budget of the National Institute of Allergy and Infectious Diseases.

For anyone holding an NIAID award in infectious disease, biodefense, or medical countermeasure development — or planning to submit one — this is the most consequential structural development of the fall. It is also widely misreported. What follows separates what is documented from what is inference.

What the agreement actually says

The stated purpose is to "support the advanced development of medical countermeasures against pandemic influenza, chemical, biological, radiological, and nuclear (CBRN) threats, and emerging infectious diseases."

That scope is narrower than "infectious disease research" generally, and broader than "biodefense" as NIAID has historically used the term. Advanced development is the operative phrase — it is the translational stage between discovery science and licensure, the space where NIH's mission has always overlapped with the Pentagon's Chemical and Biological Defense Program and with BARDA.

Four structural facts are established:

1. Ten-year term. The agreement expires in 2036, well beyond any single administration or appropriations cycle.
2. No dollar figure in the document. The $2 billion is a ceiling derived from reporting and congressional briefing, not a number written into the agreement.
3. No transfers in the current fiscal year. Per NIH, no funds move before the fiscal year ends September 30, 2026. The agreement itself was reported to be in the process of being finalized around that same date — which is also when some funds expire.
4. Project-by-project, per NIH. An NIH spokesperson stated: "This partnership will only take place on a project-by-project basis, and all research will be within the scope of NIH's mission. There is no blanket transfer of funds."

Reporting indicates internal discussions focused on transferring projects worth as much as $700 million in an initial tranche, with annual transfers potentially increasing over the decade. No specific research program has been publicly identified as losing money, and nothing has been cut.

That last point deserves emphasis, because the difference between "could transfer up to $2 billion over ten years" and "cut $2 billion from NIH" is the difference between a planning assumption and a panic.

Why this landed on NIAID specifically

The agreement did not appear in a vacuum. It is the financial expression of a reorientation that has been underway at NIAID since the start of the year.

Bhattacharya described the plan in January 2026 as "a complete transformation of [NIAID] away from this old model" — the model that historically prioritized HIV, biodefense, and pandemic preparedness. NIAID staff were subsequently directed to remove "biodefense" and "pandemic preparedness" language from research priority documents. Groups working on outbreak modeling and early detection were advised to pivot toward projects with nearer-term clinical endpoints. Long-term surveillance modeling, previously supported under preparedness funding lines, was deprioritized.

NIAID is NIH's second-largest institute, with a budget in the range of $6.6 billion. An institute that is publicly moving away from a portfolio, and a Defense Department that already runs congressionally funded medical countermeasure programs and is under budget pressure from operations, produce an obvious transaction: the work continues, the funding line changes agencies.

Congressional objection has been forceful and bipartisan in tone if not in signature. Senator Patty Murray, vice chair of Senate Appropriations, framed it as an attempt "to rob NIH of billions of dollars that Congress provided for medical research" to supplement the Pentagon's budget. House Appropriations ranking member Rosa DeLauro called the arrangement a "secretive attempt to siphon research funds away from NIH." The core legal objection is about appropriations: Congress appropriated these funds to NIH for a stated purpose, and moving them to another department's mission raises questions about reprogramming authority and congressional notification that an interagency agreement does not obviously answer.

What changes for a researcher if a project moves

This is the part almost no coverage addresses, and it is the part that determines whether a transfer is survivable for a given lab or company.

The funding instrument changes. NIH's dominant tools are grants and cooperative agreements — R01, U19, U01, and the contract vehicles NIAID runs for preclinical services. DoD's medical countermeasure work runs substantially through contracts, other transaction agreements, and program-managed acquisition vehicles. A grant is an assistance relationship with broad scientific discretion. A contract is an acquisition relationship with deliverables, milestones, and government direction. Researchers accustomed to the former frequently underestimate how different the latter feels.

Publication and data norms change. NIH awards operate under public-access expectations. DoD-funded countermeasure work operates under a review posture that can include operational security review, distribution limitations, and in some programs classification. For an academic lab whose career currency is publication, this is not a minor administrative difference.

Peer review changes. NIH study section review is investigator-initiated and scientifically adjudicated. DoD program offices select against requirement documents. Work that scores well on scientific innovation does not automatically score well against a stated military requirement.

Indirect cost treatment and institutional risk change. DoD contract vehicles apply different negotiated rate structures and different audit exposure than NIH assistance awards. Institutional research administration offices should be modeling this now, not after a transfer notice arrives.

Eligibility narrows for some performers. Foreign institutions, certain nonprofits, and organizations without facility clearances or export-control infrastructure participate in NIH science routinely and in DoD countermeasure programs rarely or not at all. A transferred project is not guaranteed to retain the same performer set.

What to actually do

If you hold an active NIAID award in the named scope — pandemic influenza, CBRN medical countermeasures, or emerging infectious disease advanced development:

Read your Notice of Award for the continuation and modification language, and confirm your current budget period end date and carryover status. Nothing moves this fiscal year, so your current period is not at risk from this agreement. Ask your program officer directly whether your project is among those under discussion for transfer; "project-by-project" means someone is making a list, and you are entitled to know whether you are on it. Document your publication expectations and any foreign collaborations now, while the record is clean, because those are the terms most likely to be renegotiated under a different instrument.

If you are preparing an NIAID submission in this space:

Do not abandon it, but do write it so it survives either outcome. Frame the aims around the biology and the clinical endpoint rather than around preparedness or biodefense as a category — that is the language NIAID has been told to stop using, and reviewers respond to the institute's stated priorities whether or not they say so. Where the work has genuine dual relevance, make that case in the significance section without making it the whole proposal.

If you are building a diversification strategy:

The corollary of money leaving NIH is money arriving somewhere else. DoD's medical countermeasure enterprise — the Joint Program Executive Office for CBRN Defense, the Defense Threat Reduction Agency, the military service medical research commands, and the Department's SBIR and STTR topics — is the receiving end of this pipeline. Registration in SAM, familiarity with broad agency announcements, and a realistic assessment of whether your institution can operate under contract rather than assistance terms are prerequisites for competing there. Organizations that begin that work in October are a year ahead of organizations that begin it when their NIH award is not renewed.

What is still genuinely unknown

Honest uncertainty is worth stating, because the coverage has not been uniformly careful.

It is not established which projects transfer, whether any transfer at all, whether Congress will block the arrangement in the FY2027 appropriations process, or whether the $700 million initial tranche survives contact with appropriators. The agreement's ten-year term makes it durable but not immune — Congress can and does condition agency spending through appropriations language, and an interagency agreement that Congress has publicly objected to is an obvious target for a rider.

What is established is the direction of travel. NIAID is being reorganized away from a portfolio it has held for two decades, and a mechanism now exists to move that portfolio's funding to another department. Researchers who plan for one of those two facts and ignore the other will be surprised twice.

This is the second structural shock to NIH's grantmaking architecture this year. Readers tracking the first should see our analysis of the NIH restructuring Congress rejected and that proceeded anyway, and, for the pandemic preparedness network specifically, NIAID's ReVAMPP investment — a program whose stated purpose sits squarely inside the scope this agreement describes.

Reporting synthesized from House Appropriations Committee statements of September 3, 2026, and subsequent coverage by Nature, Science, Inside Higher Ed, and The Hill. The memorandum of agreement has not been published in full; figures attributed to it reflect congressional briefing and press reporting. Verify current status with your NIH program officer before making funding decisions.